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Aim: Resources devoted to health care are limited, therefore setting priorities is required. It 
differs between countries whether decision-making concerning health care technologies focus 
on broad economic perspectives or whether focus is narrow on single budgets (“silo mental-
ity”). The cost perspective as one part of the full health economic analysis is important for 
decision-making. With the case of oral anticoagulants in patients with nonvalvular atrial fibril-
lation (NVAF), the aim is to discuss the implication of the use of different cost perspectives for 
decision-making and priority setting. 
Methods: In a cost analysis, the annual average total costs of five oral anticoagulants (warfarin 
and non-vitamin K oral anticoagulants [NOACs; dabigatran, rivaroxaban, apixaban, and edoxa-
ban]) used in daily clinical practice in Denmark for the prevention of stroke in NVAF patients are 
analyzed. This is done in pairwise comparisons between warfarin and each NOAC based on five 
potential cost perspectives, from a “drug cost only” perspective up to a “societal” perspective.
Results: All comparisons of warfarin and NOACs show that the cost perspective based on all 
relevant costs, ie, total costs perspective, is essential for the choice of therapy. Focusing on the 
reimbursement costs of the drugs only, warfarin is the least costly option. However, with the 
aim of therapy to prevent strokes and limit bleedings, including the economic impact of this, all 
NOACs, except rivaroxaban, result in slightly lower health care costs compared with warfarin. 
The same picture was found applying the societal perspective.
Conclusion: Many broad cost-effectiveness analyses of NOACs exist. However, in countries 
with budget focus in decision-making this information does not apply. The present study’s case 
of oral anticoagulants has shown that decision-making should be based on health care or societal 
cost perspectives for optimal use of limited resources. Otherwise, the risk is that suboptimal 
decisions will be likely.
Keywords: atrial fibrillation, oral anticoagulants, priority setting, drug costs, total costs, silo thinking
Introduction
Resources devoted to health care and to improvement of patients’ health and quality 
of life are limited. Therefore, setting priorities for use of resources between differ-
ent sectors as well as between different activities within a sector, eg, the health care 
sector, is required. Health economics and health economic analyses aim to assist 
decision-makers in rational prioritization of health care resources by taking the costs 
as well as the health improvement of a health technology, ie, drug, device, or medical 
procedure, into account.1 
Decision-making in health care may be based on narrow or broad economic per-
spectives potentially influencing the treatment recommendations. Consequently, health 
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care resource spending may result in less health improvement 
than would be achievable, if decisions were based on more 
appropriate analyses. Decision-making made with the sole 
purpose of optimizing within one budget, eg, the drug budget, 
is an example of a narrow cost perspective that may lead to a 
suboptimal priority setting. This is especially the case when 
costs and disease outcomes of the compared alternative health 
interventions differ. Health economists have named this kind 
of budgetary focus with potential suboptimal priority setting 
and use of resources as “silo thinking”.1,2 From affordability 
point of view with focus upon keeping a specific budget, the 
narrow cost perspective may make sense and is in principle 
understandable. However, the problem comes when a decision 
based on a narrow budget perspective has immediate cost 
implications for other budgets or can be followed by poten-
tial additional costs in the future shifting within the health 
care budget, budgets outside the health care sector, as well 
as costs at the societal level. In such a case, the narrow cost 
perspective should not be left alone while taking the deci-
sion regarding implementing and using a health technology.
A societal perspective of a health economic analysis is the 
broadest possible perspective. Ideally, it includes all relevant 
costs in the health care sector, costs outside the health care 
sector (eg, social care), patients’ and possible caregivers’ 
expenses (eg, transportation expenses), as well as produc-
tion loss for the society due to disease and/or early death – a 
perspective that in principle covers all costs in the society. 
Whether the decisions regarding implementation and 
use of health technologies, including coverage decision-
making, are taken with inputs from broad health economic 
perspectives or whether they are narrower differs between 
countries. Some countries base their economic input to 
decision-making on broader cost-effectiveness evidence 
either performed from the broad societal perspective or 
from broader public sector or health care sector perspec-
tives depending on the purpose of the health care sector 
in the countries. Panteli et al have recently shown that this 
is the case in some European countries like the United 
Kingdom, Ireland, Spain, Switzerland, Sweden, Finland, 
and Norway.3 In other countries, this cost-effectiveness 
approach has not been adopted or is not a prerequisite, 
hence decision-making regarding the use of health care 
technologies is often based on more narrow cost perspec-
tives, eg, the price of the drug. This is primarily the case 
in Denmark and predominantly in the hospital setting. At 
the hospital level, decision-making concerning the use 
and recommendation of specific drugs mainly focuses on 
cost information of the drug. In such a system, one could 
argue that decision-makers tend to focus more on a specific 
budget (“silo thinking”) rather than on the overall economy 
in the health care sector or in the society.
The prevalence of nonvalvular atrial fibrillation (NVAF) 
is increasing. Today, around 11 million people in the United 
States and Europe suffer from NVAF, and the number of 
patients will increase substantially during the next 30–35 
years.4–6 Patients diagnosed with NVAF are often treated 
with oral anticoagulants in order to reduce the risk of stroke. 
Currently available oral anticoagulants differ in terms of their 
ability to reduce outcomes in NVAF like stroke and all-cause 
mortality, and the implicit treatment complications like major 
bleeding, as well as they do also differ with respect to the 
need for treatment monitoring.4–7 Reducing the occurrence 
of these outcomes and the need for monitoring will result in 
reduced costs for the health care sector and other sectors (eg, 
social care) and may potentially result in productivity gains. 
Hence, these aspects should be included when analyzing the 
costs of alternative oral anticoagulants and thereby enable 
optimal priority setting and decision-making. 
The aim of this study was to focus upon the cost side of 
the health economic analysis in order to illustrate and discuss 
the implications of different cost perspectives for decision-
making, priority setting, and consequently for the optimal use 
of limited resources. A budget impact model was used as a 
tool for the cost analyses. The case presented was treatment 
with oral anticoagulants in patients with NVAF in Denmark. 
Methods
At present, there are five oral anticoagulants used in daily 
clinical practice in Denmark for the treatment of patients 
with NVAF – the vitamin K antagonist warfarin and the four 
non-vitamin K oral anticoagulants (NOACs): dabigatran, 
rivaroxaban, apixaban, and edoxaban. Each of the NOACs has 
been evaluated and compared with warfarin in large Phase III 
randomized controlled trials (RCTs) leading to their market 
authorization.8–11 Table 1 summarizes the RCT study data 
regarding the relative risk (hazard ratio [HR]) of stroke and 
bleeding of each NOAC versus warfarin.
Cost perspectives
The costs related to treatment of NVAF with oral anticoagu-
lants includes the costs of the oral anticoagulant drug itself, 
the costs of visits to monitor INR (international normalized 
ratio) levels in warfarin patients, the costs of follow-up visits 
for NOAC patients, the costs of having a stroke as well as 
the costs of having a bleeding event following the oral anti-
coagulant treatment. The number of cost elements included 
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in the cost analysis will depend on the cost perspective, as 
illustrated in Figure 1. 
The broadest cost perspective, ie, the total costs of oral 
anticoagulant treatment, includes all or most of the cost ele-
ments being either a societal perspective or a public sector 
perspective (health care and social care sectors). The narrow-
est perspective only focuses on the costs of the drug itself.
Costs estimates
To analyze the cost side of a full health economic analysis, 
a budget impact model was used when analyzing the costs 
of oral anticoagulants. This model analyzes the annual aver-
age costs of treating NVAF patients with either warfarin or 
one of the four NOACs. The cost model was based on the 
clinical evidence of absolute risk and relative risk (HR) for 
stroke and bleeding comparing warfarin with each of the four 
NOACs as found in the Phase III randomized controlled trials 
(Table 1),8–11 price per day of using oral anticoagulants based 
on pharmacy selling prices (PSP), average cost estimates of 
monitoring and follow-up visits based on available published 
Danish studies, as well as the costs of a stroke or bleeding 
event based on Danish registry studies. Costs are reported in 
US dollars (1 US$ is equal to 6.64 DKK [June 15, 2017]). 
The current price per day (PSP, including 25% value 
added tax [VAT]) for the five available anticoagulants in 
Denmark varies from US$ 194 for warfarin (3 tablets/day 
of 7.5 mg warfarin equals US$ 0.53 per day, incl VAT), 
US$ 1,180 for dabigatran (2 tablets/day equals US$ 3.23 
per day, incl VAT), US$ 1,194 for rivaroxaban (1 tablet/day 
equals US$ 3.27 per day, incl VAT), US$ 1,343 for apixaban 
(2  tablets/day equals US$ 3.68 per day, incl VAT), and finally 
US$ 1,149 for edoxaban (1 tablet/day equals US$ 3.15 per 
day, incl VAT) (www.medicinpriser.dk, accessed June 15, 
2017).12 Part of these costs are reimbursed in the primary 
care setting by the universal Danish public tax-financed health 
insurance – roughly 20% for warfarin and around 70–72% for 
NOACs (see Figures 2–5 for exact figures). The remaining 
part is paid by the patient as out-of-pocket expense. Patients 
may, however, have other drugs prescribed, leading to lower 
copayment share.
Treatment with warfarin requires regular INR monitoring 
of the patient. A report from the Danish Health Authorities 
as well as two other publications have estimated the average 
costs of INR monitoring at both the general practitioner (GP) 
setting and the hospital setting as well as with telemedicine 
solutions in Denmark.13–15 The average of these estimates, 
depending on the mode of delivery, can be calculated to an 
annual average cost of US$ 895 for the health care sector of 
INR monitoring for warfarin patients and US$ 1,212 at the 
societal level (Table 2). 
Figure 1 Different cost perspectives in oral anticoagulant therapy.
Abbreviation: inR, international normalized ratio.
1. Health care
sector
perspective
focusing on drug
budget only
(reimbursement costs)
2. Health care sector
perspective focusing
on drug prices and
costs of INR
monitoring/visits
3. Health care sector
perspective focusing
on drug prices, INR
monitoring/visits, and
stroke/bleeding
events avoided
4. Health care and
social care sector
perspective focusing
on drug prices, INR
monitoring/visits, and
stroke/bleeding
events avoided
5. Societal perspective
focusing on drug prices,
INR monitoring/visits,
stroke/bleeding events
avoided, and production
lost in society due to
events (stroke/bleedings)
Most narrow cost
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Table 1 Risk reduction in stroke and bleeding events* using NOACs compared with warfarin
RCT study data Stroke Intracranial bleeding Gastrointestinal 
bleeding
Other
bleedings
Dabigatran (Connolly et al, 2009)8
1-year event risk among warfarin patients 1.69% 0.74% 1.02% 1.60%
Relative risk (HR) in events using dabigatran 
110 mg/150 mg compared with warfarin (CI)
1.00**/0.66 
(ns: 0.91; Ci: 0.74–1.11 
/0.66; CI: 0.53–0.82)
0.31/0.40
(0.31; Ci: 0.20–0.47/0.40; 
CI: 0.27–0.60)
1.00**/1.50
(NS: 1.10; CI:0.86–1.41/ 
1.50; CI: 1.19–1.89)
1.00**/1.00**
(0.85; CI: NA /  
0.83; CI: NA)
Rivaroxaban (Patel et al, 2011)9
1 year event risk among warfarin patients 2.40% 0.73% 1.33% 1.28%
Relative risk (HR) in events using 
rivaroxaban compared with warfarin (CI)
1.00**
(0.88; CI: 0.75–1.03)
0.67
(CI: 0.30–0.58)
1.45
(CI: NA)
1.00
(0.78; CI: NA)
Apixaban (Granger et al, 2011)10
1 year event risk among warfarin patients 1.60% 0.80% 0.86% 2.27%
Relative risk (HR) in events using apixaban 
compared with warfarin (CI)
0.79
(CI: 0.66–0.95)
0.42
(CI: 0.30–0.58)
1.00**
(CI:0.7–1.15)
0.79
(CI: 0.68–0.93)
Edoxaban (Giugliano et al, 2013)11
1-year event risk among warfarin patients 1.80% 0.85% 1.23%
Relative risk (HR) in events using edoxaban 
60 mg compared with warfarin (CI)+
1.00** 
(NS: 0.87; CI: 0.73–1.04)
0.47
(CI: 0.34–0.63)
1.23
(CI: 1.02–1.50)
Notes: *“Other bleedings” are reported in some of the clinical trials. These are severe bleedings together with intracranial bleedings and gastrointestinal bleedings and 
summed up in these clinical trials as “major bleedings” following treatment. Because “other bleedings” were not reported in all four trials, these bleeding types were omitted 
from the present analysis; **all relative risks (HR) that were not found significant in the clinical trials (NS = not significant) were set to 1.0 in the cost analysis; ; +only the 60 
mg dose is included for edoxaban as this is the only approved dosage according to their SmPC.
Abbreviations: NA, not applicable; NOAC, non-vitamin K oral anticoagulants; RCT, randomized clinical trial; SmPC, Summary of Product Characteristics; CI, confidence 
interval; hR, hazard ratio.
Table 2 Annual average costs of INR monitoring of warfarin patients (US$)
INR monitoring at: Share of 
type of 
monitoring13
Danish Health 
Authorities13 
– adjusted to 2015 
charges*
Langkilde et al14
– adjusted to 2015 
charges*
Vestergaard  
et al (2015)15
Average annual 
costs of INR 
monitoring
The general practitioner 60% Us$ 492 US$ 728 Us$ 750 Us$ 657
Hospital, ambulatory visit** 39% Us$ 1,269
self-monitoring at home 1% Us$ 654
Tele-medicine monitoring 0.4% US$ 680
Distributed total costs of INR monitoring Us$ 799 Us$ 941 Us$ 954 US$ 898‡
Notes: *Cost calculations in Danish Health Authorities (Sundhedsstyrelsen, 2012)13 and in Langkilde et al. (2012)14 have for the INR monitoring in the GP setting been 
adjusted to 2015 charges16 (2015 prices); **12 annual visits assumed (one visit per month); ‡the societal annual costs of inR-monitoring are calculated to Us$ 1,212. The 
extra costs come from the patients transporting direct expenses and time used visiting the clinic for INR-monitoring following calculations by the Danish Health Authorities.13
Abbreviation: inR, international normalized ratio.
Treatment with NOACs does not require INR monitoring. 
However, the patient is expected to come to hospital ambula-
tory clinics or to their GP for follow-up visits, including for 
blood sample testing, with four visits in the first year after 
initiation of treatment and two visits the following years.17 
In the present analysis, three annual visits are conservatively 
assumed on average for the patients prescribed a NOAC at 
a cost of US$ 28 per visit.16
Oral anticoagulant treatment reduces the risk of stroke 
in patients with NVAF. At the same time, it may increase the 
risk of bleeding, thus the safety profile of the drug is equally 
important as the efficacy profile. A Danish national registry 
study covering all Danish AF patients in the period 2002–
2012 found the first 3-year total attributable societal average 
costs of a first incident stroke to be as high as US$ 30,925 
(present value).18 Similarly, the 3-year total attributable soci-
etal average costs of a first incident episode of intracranial 
bleeding were US$ 30,950, US$ 20,019 for a gastrointestinal 
bleeding episode, and US$ 13,874 for other bleeding events 
in the same AF population (present values).19 Given that this 
study analyzed all AF patients over a 10-year period, mortality 
was taken into account in the analyses when estimating the 
attributable costs due to stroke or bleeding events.18,19 The 
cost estimates found in this study are further split into the 
relevant different sectors in the budget impact analysis (health 
care, municipalities, society), and thereby the budgets that 
they impose. The risk of having stroke and bleeding events 
in NVAF patients during anticoagulation therapy as well as 
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their associated costs (as presented in Table 3) are included 
in the present study’s estimation of the total costs related to 
treatment of NVAF with oral anticoagulants.
Results
In the cost analysis, the different alternatives from the narrow-
est perspective (drug costs only) to the broadest perspective 
(societal) are analyzed, including all treatment costs, social 
care costs, and production lost. Figures 2–5 show the total 
costs per patient receiving oral anticoagulant therapy in Den-
mark for each of the four NOACs compared with warfarin 
for the five different cost perspectives in Figure 1.
All comparisons (Figures 2–5) show that the cost perspec-
tive of the analysis based on total costs per patient per year 
is central for the choice of therapy. If the cost perspective 
focuses on the reimbursement costs of the drugs only (drug 
prices minus out-of-pocket payment), ie, the drug budget of 
the public health care sector (first option in the figures), then 
warfarin is clearly the least costly option. When adding the 
costs of INR monitoring and follow-up visits to the drug bud-
get expenses (second option in the figures), all four NOACs, 
more or less, reach the cost level of the warfarin alternative. 
The aim of oral anticoagulants is to prevent strokes, while 
at the same time limiting bleeding events. Referring to the 
Table 3 Total extra costs of first-incident stroke and first-incident bleeding events in AF patients – 3-year present values (US$)
Cost elements Stroke18,19 Intracranial bleeding19 Gastrointestinal bleeding19
health care sector costs 20,507 20,234 16,235
Municipality social care costs 8,080 8,429 3,428
lost production costs 2,338 2,288 355
Total societal costs 30,925 30,950 20,019
Abbreviation: AF, atrial fibrillation.
Figure 2 Annual costs per NVAF patient receiving warfarin versus dabigatran 110 mg and 150 mg (US$).**
Notes: *Including the costs of stroke and bleedings; **annual costs for the warfarin alternative are presented in the white boxes in the figure, whereas the annual costs in 
the dabigatran alternative are presented in the gray shaded boxes.
Abbreviation: NVAF, nonvalvular atrial fibrillation.
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Figure 3 Annual costs per NVAF patient receiving warfarin versus rivaroxaban 20 mg (US$).**
Notes: *Including the costs of stroke and bleedings; **Annual costs for the Warfarin alternative are presented in the white boxes in the figure, whereas the annual costs in 
the rivaroxaban alternative are presented in the gray shaded boxes.
Abbreviation: NVAF, nonvalvular atrial fibrillation.
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Figure 4 Annual costs per NVAF patient receiving warfarin versus apixaban 5 mg (US$).**
Notes: *Including the costs of stroke and bleedings; **annual costs for the warfarin alternative are presented in the white boxes in the figure, whereas the annual costs in 
the apixaban alternative are presented in the gray shaded boxes.
Abbreviation: NVAF, nonvalvular atrial fibrillation.
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Phase III RCTs, dabigatran 150 mg and apixaban result in 
significantly less strokes than warfarin, whereas the other 
NOACs result in the same level of stroke prevention as 
warfarin (noninferiority). Furthermore, all NOACs reduce 
the risk of intracranial bleeding compared with warfarin, 
and some NOACs also reduce the risk of gastrointestinal 
bleeding, whereas other NOACs increase this particular risk 
(Table 1). When including the costs of strokes and bleeding 
events in the analysis (still with the health care sector and 
its budgets as the perspective, third option in the figures), all 
NOACs result in slightly lower health care costs compared 
with warfarin (Figures 2, 4, and 5) – except for rivaroxaban 
with costs close to the warfarin option (Figure 3). Enlarging 
the cost perspective to include costs related to social care at 
the municipality level (fourth option in the figures), selection 
of apixaban 5 mg, dabigatran 150 mg, and edoxaban 60 mg 
results in less annual costs (US$ 124 to US$ 301) compared 
with warfarin (Figures 2, 4, and 5). Finally, when analyzed 
from the societal perspective including the societal costs in 
terms of production loss and patients’ own expenses and time 
(fifth option in the figures – societal perspective), selection 
of apixaban 5 mg, dabigatran 150 mg, and edoxaban 60 mg 
still result in less annual societal costs (US$ 253 to US$ 419) 
compared with warfarin (Figures 2, 4, and 5). For rivaroxa-
ban 20 mg, the total costs including municipality costs are 
slightly higher than for warfarin, whereas rivaroxaban on the 
other hand results in slightly lower costs than for warfarin at 
the societal level, although close to being equal (Figure 3). 
Discussion
Many analyses investigating the cost-effectiveness of the 
different NOACs have been carried out. Although it is out 
of scope of the present study to assess the quality of these 
analyses, they generally conclude that NOACs are cost- 
effective.20–23 From a health economic perspective reim-
bursement, decision-making ought to be broad in terms of 
Figure 5 Annual costs per NVAF patient receiving warfarin versus edoxaban 60 mg (US$).**
Notes: *Including the costs of stroke and bleedings; **annual costs for the warfarin alternative are presented in the white boxes in the figure, whereas the annual costs in 
the edoxaban alternative are presented in the gray shaded boxes.
Abbreviation: NVAF, nonvalvular atrial fibrillation.
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evaluating both costs and outcomes of a given health inter-
vention compared with relevant alternatives. However, in 
countries with no or limited use of broader cost-effectiveness 
evidence for reimbursement as well as local implementation, 
the decisions are instead predominantly based on more nar-
row cost perspectives and a single budget focus, and by that 
broader health economic information is often not taken into 
account, even though this may lead to decision-making that is 
not optimal either in terms of deciding upon reimbursement 
or in the use of the technology. The present study focuses 
only on the cost side of the health economic analysis and 
analyzes the total costs of the different NOACs, showing the 
implications of using different cost perspectives. 
The case of oral anticoagulants demonstrates that choice 
of cost perspective is pivotal to the overall total cost results 
in the budget impact analysis when comparing alternative 
treatment options and thus important for decision-making 
and optimal priority setting. The potential recommenda-
tions for decision-making and priority setting in terms of 
the optimal treatment option with respect to the costs of the 
different alternatives differ depending on the perspective of 
the analysis. Having the narrowest cost perspective – costs of 
the drug only – warfarin compared to all NOACs is clearly 
the least expensive anticoagulant therapy. However, including 
visit costs as well as the costs of stroke and bleedings, and 
thereby broadening the cost perspective to that of the public 
sector or society, has the implication that NOACs are less 
expensive or comparable to warfarin, leading to cost savings 
or equal costs depending on the very NOAC of choice. 
The present analyses show that the total annual costs of 
anticoagulation treatment in NVAF patients are between US$ 
2,006 and US$ 2,557 using a NOAC compared with US$ 
2,358 to US$ 2,636 using warfarin. The main reasons for 
these lower costs associated with NOACs are the reduced risk 
of having a stroke linked to some of the NOACs, the lower 
risk of intracranial bleeding linked to all NOACs, as well as a 
lower risk of gastrointestinal bleeding linked to some NOACs 
compared with warfarin treatment (Table 1). 
Recently, Brunetti et al, as a proposal to the slow imple-
mentation of NOACs despite reimbursement, argued for the 
use of a budget impact approach as being more appreciated by 
the public payers, managers, and decision-makers instead of 
cost-effectiveness analyses.24 Analyzing this with a broad per-
spective including direct and indirect health care and societal 
costs, mortality gains, gain in GDP, etc., brings the break even 
for the investment in NOACs in terms of costs spend down 
to 2.5 years.24 Similarly, US budget impact and cost studies 
have also, as examples from the pespectives of the payer, 
compared the different NOACs versus warfarin specifically 
in terms of the costs of avoided stroke events and bleeding 
events induced.25–28 These studies found similar results of 
savings in the 1-year costs of NOAC treatment compared 
with warfarin due to reduced risk of stroke and bleedings, 
although the magnitude of the savings varies. In some stud-
ies, though, different NOACs resulted in higher annual costs 
compared with warfarin, eg, rivaroxaban27,28 and dabigatran26 
in patients ≥75 years of age. For rivaroxaban, this is also true 
in the present analysis with a perspective of the health care 
sector or the public sector, although cost differences are small 
(Figure 3). The US studies did not include either the costs of 
the oral anticoagulants itself or visit costs – cost elements 
that were both included in the analyses in the present study. 
Limitations
Our analysis has a number of limitations. Firstly, our analyses 
are not based on head-to-head comparisons of the NOACs, 
but on pairwise comparisons of the individual NOACs and 
warfarin in Phase III registration trials (RCTs),8–11 as no head-
to-head trials of NOACs exist. However, indirect comparisons 
are generally accepted in health science when performing 
meta-analyses and systematic reviews, as well as in health 
economic analyses and technology assessments.29 The aim 
of the present analysis was to focus upon within-trial com-
parison of warfarin to the specific NOAC in the trial and not 
to make conclusions across trials. Hence, we do not consider 
this limitation important and relevant in the present case. 
Secondly, the present analysis relies on clinical evidence 
from Phase III RCTs.8–11 The advantage is a high internal 
validity (proofs of concept), but potentially a low external 
validity, ie, it does not necessarily reflect current clinical 
practice. However, a number of recent real-world data studies 
based on retrospective information from different registries 
have in general complemented the data findings from the 
different NOAC RCTs in terms of risk reduction of stroke 
and bleeding events using these agents.30–34 Thus, the results 
of the present study are not expected to be markedly differ-
ent, if data from these real-world studies were used instead 
of those from the RCTs.
Thirdly, when compared with the different NOACs, the 
warfarin-treated patients in the present analyses utilized 
an average level of the time in therapeutic range (TTR), as 
found in the respective randomized clinical trials. However, 
applying subgroup analyses of warfarin treatment quality 
with respect to different TTR levels obtained show similar 
cost saving results for apixaban even for high TTR levels 
of warfarin treatment (TTR levels in percentages between 
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71.2 and 83.2) as found in the base case analysis.35 Similarly, 
consistency is found on the comparison of apixaban with 
warfarin patients being less well controlled (TTR levels in 
percentages between 24.3 and 60.5).35
Fourthly, some NOACs (apixaban and edoxaban) have 
shown significantly lower risk of “other bleedings” compared 
with warfarin.10,11 Due to missing data for some NOACs 
regarding this bleeding outcome and potentially derived 
costs, these bleeding events were not included. The inclusion 
of “other bleedings” in the cost calculation would, at least 
for one of the two NOACs, had resulted in even larger cost 
savings compared with warfarin. This is true for part of the 
NOAC group, in particular apixaban, where a reduction in all-
cause mortality has been found.8,11 Gains in mortality were, 
however, not included in the analyses of the present study. If 
all-cause mortality gains were included in the analyses this 
would have been a further upside for apixaban compared 
with warfarin, as also argued by Brunetti et al.24
Fifthly, the study only analyzed the annual costs of the dif-
ferent treatment options and not their long-term costs. Should 
the 1-year risk reductions in terms of stroke and bleedings 
found in the clinical trials for the different NOACs versus 
warfarin differ over a longer time horizon of treatment, this 
might influence the cost difference between the alternatives. 
This would likely have been the case if all patients included 
in these trials were newly diagnosed AF patients receiving 
their first anticoagulation treatment by inclusion in the trial. 
However, the clinical trials (eg, Granger et al10) did not have 
this requirement with patients to be included just fulfilling 
certain criteria for having an AF diagnosis. In this respect, the 
annual risk reductions found in terms of stroke and bleeding 
summarizes the average annual risk of events for a broader 
range of AF patients and not only newly diagnosed, eg, 40% 
in apixaban study.10 Hence, the results found in the present 
study are expected to more or less represent the annual total 
costs in a given year, and thus in principle it should be pos-
sible to multiply this annual cost with number of years to 
estimate the long-term cost expression. 
Sixthly, four follow-up GP visits are recommended in the 
first year after initiation of NOAC treatment.17 In the present 
analyses, an average of three visits was assumed. The number 
of visits after the first year is typically reduced to 2–3 visits 
for NOAC patients, based on individual clinical judgment. 
The present analyses are based on a standard year and not 
the first year with more intense INR monitoring for warfarin 
patients. If considering only the first year of NOAC treatment 
with four visits, the total costs of NOACs come slightly closer 
to the costs of warfarin, although still being lower than that 
of warfarin in the analysis based on the societal perspective.
Seventhly, the present analyses only include those costs 
related to the municipality social care resource, which is 
available from the national registries in Denmark. It is, 
however, well-known that these registries do not include all 
resources used at the municipality level, hence the costs of 
social care, including both stroke and bleeding events, are 
an underestimation of the true costs. 
Finally, VAT (25%) is included in the drug costs used 
in the analyses due to the focus upon budgets. However, in 
economic theory VAT is a transfer payment and not a true 
use of resources, thereby it can be argued that the VAT part 
should not be included in health economic analyses. Includ-
ing VAT in the analyses is not an advantage for the NOAC 
alternatives due to their higher drug costs compared with 
warfarin, which makes the results of the analyses conserva-
tive. Omitting VAT on drug prices increases the difference 
in total costs between the NOACs and warfarin. 
Conclusion
The analyses of the cost side in health economic analyses 
using a budget impact model approach have shown the 
importance of analyzing costs from a broader cost perspec-
tive than just a focus on drug prices. For optimal use of 
limited resources in society and/or the health care sector, 
priorities should be made at the broadest possible and most 
relevant perspective in terms of the overall aim of the health 
care sector. This implies that health economic analyses on 
the cost side should at least cover all relevant cost implicat-
ing activities in the health care sector, and may also have to 
include costs in other sectors that are affected as well. If the 
overall aim of the health care priorities is to keep citizens as 
healthy and productive as possible, the societal perspective 
ought to be chosen. Even though narrow cost perspectives 
and budget focus may well be relevant for decision-making 
at local levels, broader costs perspectives have to be con-
sidered to identify potential costs shifting within the health 
care budget, other budgets, as well as costs at the societal 
level. This will avoid the risk that priority setting may not 
be optimal, as illustrated with oral anticoagulants in the 
present analysis.
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